Overview Xolair in Patients With Chronic Sinusitis Status: Completed Trial end date: 2009-01-01 Target enrollment: Participant gender: Summary The purpose of this study is to determine if treatment with the anti-IgE antibody, Xolair (omalizumab), will improve objective and subjective evidence of chronic sinusitis. Phase: Phase 4 Details Lead Sponsor: University of ChicagoCollaborators: Genentech, Inc.Novartis PharmaceuticalsTreatments: AntibodiesAntibodies, Anti-IdiotypicImmunoglobulinsOmalizumab